Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its ...
Medical diagnostic and testing concern ProPhase Labs, Inc. gets put in the spotlight today. ProPhase Labs, Inc. has seen huge revenue growth from Covid testing but is rapidly diversifying into other ...
UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. A live question and answer session ...
ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations and ...
Visit a quote page and your recently viewed tickers will be displayed here.
ProPhase Labs received a 180-day extension from Nasdaq to meet its $1.00 bid price compliance requirement. ProPhase Labs Inc. announced that it has received a 180-day extension from Nasdaq to meet the ...
The latest price target for ProPhase Labs (NASDAQ:PRPH) was reported by HC Wainwright & Co. on February 21, 2024. The analyst firm set a price target for $11.00 expecting PRPH to rise to within 12 ...
In a challenging market environment, ProPhase Labs, Inc. (PRPH) stock has touched a 52-week low, reaching a price level of $1.99. This latest dip underscores a difficult period for the company, which ...
In a challenging market environment, ProPhase Labs, Inc. (PRPH) stock has touched a 52-week low, reaching a price level of $1.99. This latest dip underscores a difficult period for the company, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results